POXEL S.A., a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced the successful private placement of 2,358,483 new ordinary shares, each with a nominal value of €0.02 per share, reserved to a specified category of investors.
May 25, 2020
· 12 min read